Bavarian Nordic
Denmark - Kvistgard
BiotechnologyFocus: Vaccines
Bavarian Nordic is a life sciences company focused on Vaccines.
Infectious DiseasesVaccines
Employees
1001-5000
Open Jobs
25
Pipeline & Clinical Trials
Blood draw
MonkeypoxClinical Trials (1)
NCT03745131Cohort Study of Healthcare Workers Receiving Imvanex®
N/AVivotif
Typhoid FeverClinical Trials (1)
NCT02391909Phase 4 Study To Assess The Safety Of Vivotif At Different Release Titers Among Travelers
N/AMVA-BN
SmallpoxClinical Trials (1)
NCT00189943Study on Safety, Tolerability and Immunogenicity of an MVA Vaccine Administered to Healthy Subjects
Phase 1MVA-BN-Brachyury/ FPV-Brachyury
Safety IssuesClinical Trials (1)
NCT03349983Safety and Tolerability Trial (MVA-BN-Brachyury/FPV-Brachyury)
Phase 1TAEK-VAC-HerBy
ChordomaClinical Trials (1)
NCT04246671TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer
Phase 1MVA-BN-Brachyury
Solid Metastatic TumorClinical Trials (1)
NCT04134312A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer
Phase 1MVA BN RSV
Respiratory Syncytial Virus InfectionsClinical Trials (1)
NCT02419391Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA BN® RSV Vaccine
Phase 1IMVAMUNE
Dermatitis, AtopicClinical Trials (1)
NCT00189917Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in Patients With Atopic Disorders
Phase 1MVA-BN-HER2
Breast CancerClinical Trials (1)
NCT00485277A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Metastatic Breast Cancer
Phase 1MVA-mBN32
HIV InfectionsClinical Trials (1)
NCT00386633Safety and Immunogenicity Study of Recombinant Modified Vaccinia Virus Ankara (MVA) Virus to Treat HIV Infection
Phase 1Phase 1
PXVX0200
CholeraClinical Trials (1)
NCT01585181Safety and Immunogenicity of the Live Oral Cholera Vaccine Candidate PXVX0200
Phase 1MVA-mBN120B
HIV InfectionsClinical Trials (1)
NCT00623259Phase I Safety Study of a Recombinant MVA HIV Multiantigen Vaccine in HIV-infected Subjects
Phase 1Elstree-BN
SmallpoxClinical Trials (1)
NCT00189969Take Rate, Immunogenicity and Safety of Elstree-BN Smallpox Vaccine in Healthy Vaccinia-Naive Subjects
Phase 1MVA-BN-PRO
Androgen-insensitive Prostate CancerClinical Trials (1)
NCT00629057A Safety Trial of MVA-BN®-PRO in Men With Androgen-Insensitive Prostate Cancer
Phase 1MVA-BN-WEV Dose 1
Equine EncephalitisClinical Trials (1)
NCT04131595Vaccination Trial of a Recombinant MVA-BN-WEV Vaccine in Healthy Adult Subjects
Phase 1Phase 1
Clinical Trials (1)
NCT02840994A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer
Phase 1MVA-BN-HER2
Breast CancerClinical Trials (1)
NCT01152398A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Breast Cancer After Adjuvant Therapy
Phase 1MVA-BN-RSV
Respiratory Syncytial Virus InfectionsClinical Trials (1)
NCT02864628RSV-MVA-BN Vaccine Phase I Trial, Intranasal Application in Adults.
Phase 1EP-1233
HIV InfectionsClinical Trials (1)
NCT00428337Safety of and Immune Response to a DNA Vaccine and a Recombinant HIV-1-MVA Vaccine, Separately and in Combination, in Healthy Adults
Phase 1Durvalumab
Metastatic Colorectal CancerClinical Trials (1)
NCT03376659Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma
Phase 1/2Ad26.HPV16
Human Papillomavirus InfectionsMVA-mBN32
HIV InfectionsClinical Trials (1)
NCT00390078Single-Blind, Controlled Safety and Immunogenicity Study of Recombinant MVA Virus to Treat HIV Infection
Phase 1/2IMVAMUNE
HIV InfectionsClinical Trials (1)
NCT00189904Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in HIV Infected Patients
Phase 1/2IMVAMUNE®
SmallpoxClinical Trials (1)
NCT02038881Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection
Phase 2IMVAMUNE
SmallpoxClinical Trials (1)
NCT00189956Dose-finding Study to Evaluate Immunogenicity of Three Different Dose Levels of the IMVAMUNE (MVA-BN) Smallpox Vaccine.
Phase 2PROSTVAC V/F
Prostatic NeoplasmsClinical Trials (1)
NCT02506114Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer
Phase 2MVA-BN-RSV
Respiratory Syncytial Virus InfectionsClinical Trials (1)
NCT02873286RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults
Phase 2BN-Brachyury plus radiation
ChordomaClinical Trials (1)
NCT03595228BN Brachyury and Radiation in Chordoma
Phase 2MVA-BN
Monkeypox (Mpox)Clinical Trials (1)
NCT06549530Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children From 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus Infections
Phase 2IMVAMUNE
HIV InfectionsClinical Trials (1)
NCT00316589Safety and Immunogenicity of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in HIV Infected Patients
Phase 2MVA-mBN85B
MeaslesClinical Trials (1)
NCT00891007Study to Evaluate Safety, Dose Response and Immunogenicity of the Measles Vaccine MVA mBN85B in Healthy Children Aged 6 Months to 6 Years
Phase 2ABNCoV2 100ug
COVID-19 DiseaseClinical Trials (1)
NCT05077267ABNCoV2 Vaccine in SARS-CoV-2 (COVID-19) Seronegative and Seropositive Adult Subjects
Phase 2CHIKV VLP, adjuvanted
Chikungunya VirusClinical Trials (1)
NCT05065983A Study to Assess the Safety and Immunogenicity of PXVX0317 Chikungunya Virus Virus-Like Particle Vaccine
Phase 2MVA-BN®
SmallpoxClinical Trials (1)
NCT00316524A Randomized, Double-blind, Placebo-controlled Study on Immunogenicity and Safety of MVA-BN (IMVAMUNE™) Smallpox Vaccine in Healthy Subjects
Phase 2IMVAMUNE
SmallpoxClinical Trials (1)
NCT00857493A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects
Phase 2IMVAMUNE
Atopic DermatitisClinical Trials (1)
NCT00316602A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in Subjects With Atopic Dermatitis
Phase 2LF formulation of IMVAMUNE®
SmallpoxClinical Trials (1)
NCT01668537A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects
Phase 2mFOLFOX6
Metastatic Colorectal CancerMVA-mBN294B
RSV InfectionClinical Trials (1)
NCT04752644Phase 2a Study of MVA-BN-RSV Vaccination and RSV Challenge in Healthy Adults
Phase 2MVA-nef
HIV InfectionClinical Trials (1)
NCT00189930An Evaluation of Immunogenicity and Safety of Two Doses of MVA-nef vs. MVA-BN in HIV-1 Infected Patients
Phase 2MVA-BN-WEV
EncephalitisClinical Trials (1)
NCT06899802A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine
Phase 2IMVAMUNE
SmallpoxClinical Trials (1)
NCT00686582An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 Vaccinees
Phase 2PROSTVAC-V/F
Prostatic NeoplasmsClinical Trials (1)
NCT02772562Adjuvant PROSTVAC-V/F in Subjects at High Risk for Relapse After Radical Prostatectomy
Phase 2CHIKV VLP/unadjuvanted
Chikungunya Virus InfectionClinical Trials (1)
NCT03483961Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults
Phase 2MVA-BN-Brachyury
Prostate AdenocarcinomaClinical Trials (1)
NCT04020094Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And High-Risk Localized Prostate Cancer
Phase 2Chikungunya
ChikungunyaClinical Trials (1)
NCT03992872Phase 2 Open-label Study of Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317)
Phase 2CV301
Bladder CancerClinical Trials (1)
NCT03628716CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Phase 2PROSTVAC®-VF/TRICOM™
Prostate CancerClinical Trials (1)
NCT00078585PROSTVAC®-VF/TRICOM™ Vaccine for the Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy
Phase 2Jynneos
Monkeypox (Mpox)Clinical Trials (1)
NCT07199569Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells
Phase 2Open Jobs (25)
Purchaser (f/m/d) – Direct Materials
Bern
Yesterday
Senior Supply Planner
Kvistgaard
1w ago
Payroll Accountant
Hellerup
1w ago
Integration Solution Architect
Hellerup
1w ago
Student Assistant for Accounting
Hellerup
2w ago
Senior Scientist (f/m/d) - Immunomonitoring
Martinsried
2w ago
Student Assistant Corporate Communications
Hellerup
2w ago
Fachmitarbeiter Packaging/Finishing (w/m/d)
Bern
2w ago
Validation & Compliance Professional (m/f/d)
Martinsried
2w ago
Facility Asset Coordinator (w/m/d)
Martinsried
2w ago
Containment Engineer
Kvistgaard
3w ago
Senior Quality Assurance Specialist - GVP
Martinsried
4w ago
Lab Equipment Application Specialist
Kvistgaard
1mo ago
Global Process Manager, Inbound to Outbound
Kvistgaard
1mo ago
Global Process Manager, Source to Pay
Kvistgaard
1mo ago
IT Supporter (m/f/d)
Bern
1mo ago
QA IT Specialist
Kvistgaard
1mo ago
Manager Capital Projects (m/f/d)
Bern
1mo ago
Operator Biological Manufacturing (w/m/d)
Bern
1mo ago
Laboratory Assistant (m/f/d)
Martinsried
1mo ago
Technician Quality Control in vivo (f/m/d)
Martinsried
1mo ago
Sales Representative (w/m/d) Impfstoffe – Region Göppingen, Nürtingen
Martinsried
1mo ago
Sales Representative Impfstoffe - Region Rosenheim, Bad Reichenhall, Mühldorf a. Inn
Martinsried
2mo ago
Director Regulatory Affairs, CMC
Kvistgaard
2mo ago
Head of Medical Affairs & GCSP (Global Clinical Safety & Pharmacovigilance)
Durham
2mo ago
$325K - $415K/yr
Interview Prep Quick Facts
Portfolio: 63 clinical trials
Top TAs: Infectious Diseases, Oncology, Respiratory
Open Roles: 25 active jobs
Therapeutic Area Focus
Infectious Diseases
9 pipeline
Oncology
9 pipeline
Respiratory
4 pipeline
Dermatology
1 pipeline
Immunology
1 pipeline
Vaccines
1 pipeline
Marketed
Pipeline
Hiring Trend
Slowing Down
25
Open Roles
+5
Added
-11
Filled/Removed
Based on last 4 crawl cycles